Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Gains from Investment Securities (2020 - 2025)

Keros Therapeutics filings provide 6 years of Gains from Investment Securities readings, the most recent being -$14000.0 for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 99.76% to -$14000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$14000.0, a N/A change, with the full-year FY2023 number at $1.3 million, down 91.32% from a year prior.
  • Gains from Investment Securities hit -$14000.0 in Q4 2025 for Keros Therapeutics, up from -$5.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $15.4 million in Q4 2022 to a low of -$5.7 million in Q4 2024.
  • Median Gains from Investment Securities over the past 5 years was -$4000.0 (2023), compared with a mean of $2.4 million.
  • Biggest five-year swings in Gains from Investment Securities: soared 40.91% in 2021 and later skyrocketed 59419.23% in 2022.
  • Keros Therapeutics' Gains from Investment Securities stood at -$26000.0 in 2021, then skyrocketed by 59419.23% to $15.4 million in 2022, then plummeted by 91.3% to $1.3 million in 2023, then plummeted by 527.5% to -$5.7 million in 2024, then skyrocketed by 99.76% to -$14000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were -$14000.0 (Q4 2025), -$5.7 million (Q4 2024), and $5.7 million (Q3 2024) per Business Quant data.